Skip to main content

Advertisement

Log in

Expression and prognostic relevance of CD44v6 in stage I non-small cell lung carcinoma

  • Original Paper
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Purpose

Expression of CD44 and its variants has been shown to be relevant to tumor progression in various human malignancies. We evaluated the expression of CD44v6 in the primary lesions of stage I non-small cell lung cancer (NSCLC) and correlated the expression level to its prognosis.

Methods

The expression of CD44v6, measured by immunohistochemistry, was assessed in the tumor specimens from 190 patients with stage I NSCLC. Each slide was assigned a score: the average of the score of tumor cells staining multiplied by the score of staining intensity. And depending on the cut-off score based on receiver operating characteristic (ROC) curve analysis, the CD44v6 expression was categorized into high- and low-level groups, which were then correlated directly with the clinical outcomes.

Results

The high expression of CD44v6 was detected more frequently in the squamous cell carcinoma (38 of 71 patients, 53.5%) than in the other types of carcinoma (p < 0.05). The Kaplan–Meier survival curves showed that high level expression of CD44v6 indicated a better post-operative survival (p = 0.006), especially for stage IB disease (p = 0.049) and squamous cell carcinoma (p = 0.029). The multivariate analysis also confirmed that the expression of CD44v6 was an independent prognostic indicator (p = 0.011).

Conclusions

CD44v6 might be correlated with histogenesis of NSCLC, and its decreased expression may be an adverse prognostic indicator for the patients with stage I NSCLC, especially for those with stage IB diseases. Patients of this subgroup might need adjuvant therapy additionally.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  • ASCO (1997) Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, by the American Society of Clinical Oncology. J Clin Oncol 15(8):2996–3018

    Google Scholar 

  • Bains MS (1991) Surgical treatment of lung cancer. Chest 100(3):826–837

    Article  CAS  PubMed  Google Scholar 

  • Carter WG, Wayner EA (1988) Characterization of the class III collagen receptor, a phosphorylated, transmembrane glycoprotein expressed in nucleated human cells. J Biol Chem 263(9):4193–4201

    CAS  PubMed  Google Scholar 

  • Coradini D, Zorzet S, Rossin R et al (2004) Inhibition of hepatocellular carcinomas in vitro and hepatic metastases in vivo in mice by the histone deacetylase inhibitor HA-But. Clin Cancer Res 10(14):4822–4830

    Article  CAS  PubMed  Google Scholar 

  • Dong WG, Sun XM, Yu BP, Luo HS, Yu JP (2003) Role of VEGF and CD44v6 in differentiating benign from malignant ascites. World J Gastroenterol 9(11):2596–2600

    CAS  PubMed  Google Scholar 

  • Fasano M, Sabatini MT, Wieczorek R, Sidhu G, Goswami S, Jagirdar J (1997) CD44 and its v6 spliced variant in lung tumors: a role in histogenesis. Cancer 80(1):34–41

    Article  CAS  PubMed  Google Scholar 

  • Gunthert U, Hofmann M, Rudy W et al (1991) A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 65(1):13–24

    Article  CAS  PubMed  Google Scholar 

  • Hanley JA (1989) Receiver operating characteristic (ROC) methodology: the state of the art. Crit Rev Diagn Imaging 29(3):307–335

    CAS  PubMed  Google Scholar 

  • Harn HJ, Ho LI, Shyu RY et al (1996) Soluble CD44 isoforms in serum as potential markers of metastatic gastric carcinoma. J Clin Gastroenterol 22(2):107–110

    Article  CAS  PubMed  Google Scholar 

  • Hirata T, Fukuse T, Naiki H, Hitomi S, Wada H (1998) Expression of CD44 variant exon 6 in stage I non-small cell lung carcinoma as a prognostic factor. Cancer Res 58(6):1108–1110

    CAS  PubMed  Google Scholar 

  • Kaufmann M, Heider KH, Sinn HP, von MG, Ponta H, Herrlich P (1995) CD44 variant exon epitopes in primary breast cancer and length of survival. Lancet 345(8950):615–619

    Article  CAS  PubMed  Google Scholar 

  • Kuhn S, Koch M, Nubel T et al (2007) A complex of EpCAM, claudin-7, CD44 variant isoforms, and tetraspanins promotes colorectal cancer progression. Mol Cancer Res 5(6):553–567

    Article  CAS  PubMed  Google Scholar 

  • Manten-Horst E, Danen EH, Smit L et al (1995) Expression of CD44 splice variants in human cutaneous melanoma and melanoma cell lines is related to tumor progression and metastatic potential. Int J Cancer 64(3):182–188

    Article  CAS  PubMed  Google Scholar 

  • Marhaba R, Zoller M (2004) CD44 in cancer progression: adhesion, migration and growth regulation. J Mol Histol 35(3):211–231

    Article  CAS  PubMed  Google Scholar 

  • Miwa T, Watanabe A, Yamada Y et al (1996) Progression in gastric carcinoma relative to the ratio of CD44 epithelial variant transcript to CD44 hematopoietic variant transcript. Cancer 77(1):25–29

    Article  CAS  PubMed  Google Scholar 

  • Miyoshi T, Kondo K, Hino N, Uyama T, Monden Y (1997) The expression of the CD44 variant exon 6 is associated with lymph node metastasis in non-small cell lung cancer. Clin Cancer Res 3(8):1289–1297

    CAS  PubMed  Google Scholar 

  • Mulder JW, Kruyt PM, Sewnath M et al (1994) Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins. Lancet 344(8935):1470–1472

    Article  CAS  PubMed  Google Scholar 

  • Naor D, Sionov RV, Ish-Shalom D (1997) CD44: structure, function, and association with the malignant process. Adv Cancer Res 71:241–319

    Article  CAS  PubMed  Google Scholar 

  • Ramasami S, Kerr KM, Chapman AD, King G, Cockburn JS, Jeffrey RR (2000) Expression of CD44v6 but not E-cadherin or beta-catenin influences prognosis in primary pulmonary adenocarcinoma. J Pathol 192(4):427–432

    Article  CAS  PubMed  Google Scholar 

  • Rudzki Z, Jothy S (1997) CD44 and the adhesion of neoplastic cells. Mol Pathol 50(2):57–71

    Article  CAS  PubMed  Google Scholar 

  • Spira A, Ettinger DS (2004) Multidisciplinary management of lung cancer. N Engl J Med 350(4):379–392

    Article  CAS  PubMed  Google Scholar 

  • St JT, Meyer J, Idzerda R, Gallatin WM (1990) Expression of CD44 confers a new adhesive phenotype on transfected cells. Cell 60(1):45–52

    Article  Google Scholar 

  • Stamenkovic I, Amiot M, Pesando JM, Seed B (1989) A lymphocyte molecule implicated in lymph node homing is a member of the cartilage link protein family. Cell 56(6):1057–1062

    Article  CAS  PubMed  Google Scholar 

  • Stauder R, Eisterer W, Thaler J, Gunthert U (1995) CD44 variant isoforms in non-Hodgkin’s lymphoma: a new independent prognostic factor. Blood 85(10):2885–2899

    CAS  PubMed  Google Scholar 

  • Suzuki H, Yamashiro K (2002) Reduced expression of CD44 v3 and v6 is related to invasion in lung adenocarcinoma. Lung Cancer 38(2):137–141

    Article  PubMed  Google Scholar 

  • Tran TA, Kallakury BV, Sheehan CE, Ross JS (1997) Expression of CD44 standard form and variant isoforms in non-small cell lung carcinomas. Hum Pathol 28(7):809–814

    Article  CAS  PubMed  Google Scholar 

  • Wielenga VJ, Heider KH, Offerhaus GJ et al (1993) Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. Cancer Res 53(20):4754–4756

    CAS  PubMed  Google Scholar 

  • Wimmel A, Schilli M, Kaiser U et al (1997) Preferential histiotypic expression of CD44-isoforms in human lung cancer. Lung Cancer 16(2–3):151–172

    Article  CAS  PubMed  Google Scholar 

  • Zhu ZH, Sun BY, Ma Y et al (2009) Three immunomarker support vector machines-based prognostic classifiers for stage IB non-small-cell lung cancer. J Clin Oncol 27(7):1091–1099

    Article  PubMed  Google Scholar 

  • Zlobec I, Steele R, Terracciano L, Jass JR, Lugli A (2007) Selecting immunohistochemical cut-off scores for novel biomarkers of progression and survival in colorectal cancer. J Clin Pathol 60(10):1112–1116

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by the grant from Sun Yat-sen University Clinical Research 5010 plan ChiCTR-TRC-00000142.

Conflict of interest statement

We declare that we have no conflict of interest.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Zhihua Zhu.

Additional information

D. Situ, H. Long, P. Lin and Z. Zhu contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Situ, D., Long, H., Lin, P. et al. Expression and prognostic relevance of CD44v6 in stage I non-small cell lung carcinoma. J Cancer Res Clin Oncol 136, 1213–1219 (2010). https://doi.org/10.1007/s00432-010-0771-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-010-0771-5

Keywords

Navigation